← Eichor
Study identifier: NCT06183268 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy

Condition: Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma · Head and Neck Carcinoma  ·  Sponsor: Covenant Health Cancer Center

PhaseNA
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This purpose of this study is to examine skin reactions (called radiation dermatitis) that occur during pencil beam scanning (PBS) proton therapy. The researchers will test a unique technique called "Spot Delete" to see if it can reduce skin reactions for head \& neck patients treated with PBS. The investigators will also use a special computer model to study how the energy of the proton beam (linear energy transfer) is related to these skin reactions. The study involves creating a treatment plan based on a CT scan, which helps guide the proton beam in the body.

This description comes directly from the study's public registry record.

Talk to the study team

Samantha Hedrick, PhD, DABR  ·  865-862-1600  ·  shedrick@CovHlth.com

Catherine Duke-Taylor, BS  ·  865-862-1600  ·  cduke@CovHlth.com

Always discuss trial participation with your own doctor first.

Locations (1)

Thompson Proton CenterKnoxville, Tennessee, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06183268